hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06323460, orgStudyIdInfo id: OSU-23083, secondaryIdInfos id: NCI-2024-00904, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), briefTitle: Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Ohio State University Comprehensive Cancer Center, class: OTHER, descriptionModule briefSummary: This phase II trial studies how well using circulating tumor deoxyribonucleic acid (DNA) to guide lower dose radiation therapy works in treating patients with human papillomavirus infection (HPV)-associated oropharyngeal cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Recently, a blood test has been developed to detect the human papillomavirus in the blood and determine how many viral particles are present. Researchers want to compare any good and bad effects of using the lower dose radiation therapy with chemotherapy compared to the usual standard of care dose chemotherapy in patients who clear the human papillomavirus particles from their blood., conditionsModule conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, conditions: Oropharyngeal Squamous Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Biospecimen Collection, interventions name: Carboplatin, interventions name: Cisplatin, interventions name: Computed Tomography, interventions name: External Beam Radiation Therapy, interventions name: Paclitaxel, interventions name: Positron Emission Tomography, interventions name: Questionnaire Administration, outcomesModule primaryOutcomes measure: Positron emission tomography complete response, secondaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Incidence of adverse events, secondaryOutcomes measure: Quality of life (QOL), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ohio State University Comprehensive Cancer Center, status: RECRUITING, city: Columbus, state: Ohio, zip: 43210, country: United States, contacts name: Sujith Baliga, role: CONTACT, phone: 614-293-5066, email: Sujith.baliga@osumc.edu, contacts name: Sujith Baliga, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.96118, lon: -82.99879, hasResults: False
protocolSection identificationModule nctId: NCT06323447, orgStudyIdInfo id: PC002, briefTitle: Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia, acronym: PC002, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-05-28, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Leuko Labs, Inc., class: INDUSTRY, descriptionModule briefSummary: Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy., conditionsModule conditions: Diffuse Large B Cell Lymphoma, conditions: Multiple Myeloma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 210, type: ESTIMATED, armsInterventionsModule interventions name: PointCheck, outcomesModule primaryOutcomes measure: PointCheck Accuracy, secondaryOutcomes measure: PointCheck Precision, secondaryOutcomes measure: PointCheck Usability, secondaryOutcomes measure: PointCheck Errors, secondaryOutcomes measure: PointCheck Safety, eligibilityModule sex: ALL, minimumAge: 10 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323421, orgStudyIdInfo id: STUDY2023-1359, briefTitle: Targeting Chronic Stress for Reducing Risk Factors for Colorectal Cancer, acronym: MindCRC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-22, primaryCompletionDateStruct date: 2025-04-15, completionDateStruct date: 2025-08-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: University of Illinois at Chicago, class: OTHER, descriptionModule briefSummary: Many neighborhoods in Chicago experience daily exposure to stressors including economic inopportunity and violent crime in public spaces. There is mounting evidence that chronic psychosocial stress can facilitate carcinogenesis by modulating the gut microbiome and immune system. The proposed research aims to study the practice of mindfulness to mitigate CPS and reduce colorectal cancer risk factors among Black American women at elevated risk., conditionsModule conditions: Mindfulness, conditions: Colon Cancer, conditions: Females, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Mindfulness, outcomesModule primaryOutcomes measure: Feasibility measures, primaryOutcomes measure: Acceptability, otherOutcomes measure: Body mass index, otherOutcomes measure: Stress measure, otherOutcomes measure: Fasting glucose, otherOutcomes measure: Gut microbiota composition, otherOutcomes measure: Gut inflammation, otherOutcomes measure: Adiposity, otherOutcomes measure: Epinephrine, otherOutcomes measure: Norepinephrine, otherOutcomes measure: Cortisol, otherOutcomes measure: Resting heart rate, otherOutcomes measure: Blood lipids, otherOutcomes measure: Fasting insulin, otherOutcomes measure: Hemoglobin A1c, otherOutcomes measure: Systemic inflammation, eligibilityModule sex: FEMALE, minimumAge: 45 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Illinois at Chicago, city: Chicago, state: Illinois, zip: 60612, country: United States, contacts name: Lisa Tussing-Humphreys, PhD, role: CONTACT, phone: 312-355-5521, email: tussing@uic.edu, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06323408, orgStudyIdInfo id: BZKF-AYA_1.0, briefTitle: Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas, acronym: BZKF-AYA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: University Hospital Regensburg, class: OTHER, descriptionModule briefSummary: The treatment of adolescents and young adults (AYA, 15 to 39 years) with malignant intra-axial CNS parenchymal tumors such as IDH-mutated gliomas, medulloblastomas and ependymomas is still not curative in all cases. The tumor biology and clinical needs to diagnose and treat these tumors are comparable across all age groups, so an integrated treatment environment overseen by adult and pediatric neuro-oncology specialists seems promising to leverage synergisms and advance diagnostic and therapeutic development in these tumors. A comprehensive, prospective and integrated biomaterial and imaging-based pipeline for the multi-faceted evaluation of AYAs has not yet been established for AYA patients with brain tumors in Germany. Current diagnostic platforms neglect the integrative processing of data from MRI and FET-PET imaging, radiotherapy plans, tumor tissue, liquid biopsies and clinical data as well as prognostic markers. A prospective AYA pipeline can therefore enable a better understanding of the aforementioned high-risk CNS malignancies and promises clinical advances for AYA patients and the clinical and scientific research landscape., conditionsModule conditions: Glioma, Malignant, conditions: Embryonal Tumor, conditions: Medulloblastoma, conditions: Ependymoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: Tissue, blood, cerebrospinal-spinal fluid, outcomesModule primaryOutcomes measure: AI processing of MRI fand PET or diagnosis, primaryOutcomes measure: AI processing of MRI and PET for evaluation of response and relapse, primaryOutcomes measure: Quality control analysis in radiotherapy, primaryOutcomes measure: Analysis of response in liquid biopsies, primaryOutcomes measure: Target molecules in tissue and liquid biopsies, primaryOutcomes measure: Evaluation of progression free survival, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 39 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323382, orgStudyIdInfo id: Liver Project 6, briefTitle: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced hepatocellular carcinoma. We aimed to describe the efficacy and safety of locoregional therapy combined with Bevacizumab and PD1/L1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy., conditionsModule conditions: Advanced Hepatocellular Carcinoma, conditions: Anti-PD1/PDL1 Antibody, conditions: Bevacizumab, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: Locoregional therapy, interventions name: Bevacizumab, interventions name: Atezolizumab, interventions name: Tislelizumab, interventions name: Toripalimab, interventions name: Sintilimab, interventions name: Camrelizumab, outcomesModule primaryOutcomes measure: Progression-Free-Survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chinese PLA hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100853, country: China, contacts name: Qunfang Zhou, Md, role: CONTACT, phone: 8619868000115, email: zhouqun988509@163.com, contacts name: MD, role: CONTACT, phone: 8613910984586, email: duanfeng@vip.sina.com, contacts name: Feng Duan, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06323369, orgStudyIdInfo id: SYSKY-2023-1283-02, briefTitle: Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2029-03-25, completionDateStruct date: 2029-09-25, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, class: OTHER, descriptionModule briefSummary: A prospective, randomized, open-label, multicenter Phase 2 trial designed to compare the efficacy and safety of Tislelizumab combined with chemotherapy followed by surgery versus up-front surgery in resectable clinically node-negative head and neck squamous cell carcinoma., conditionsModule conditions: Head and Neck Squamous Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 154, type: ESTIMATED, armsInterventionsModule interventions name: Tislelizumab（neoadjuvant）, interventions name: Cisplatin （neoadjuvant）, interventions name: Nab-paclitaxel （neoadjuvant）, interventions name: Surgical resection, interventions name: Cisplatin（adjuvant）, interventions name: Tislelizumab（adjuvant）, interventions name: Radiation, interventions name: Carboplatin（neoadjuvant）, interventions name: Carboplatin（adjuvant）, outcomesModule primaryOutcomes measure: Disease-Free Survival(DFS ), primaryOutcomes measure: Lymph node positivity rate, secondaryOutcomes measure: Percentage of Participants Who Experienced High-Grade (Grade 3-4 and Grade 5) Adverse Events, secondaryOutcomes measure: Pathological complete response (pCR) rate, secondaryOutcomes measure: Major Pathological Response (MPR) rate, secondaryOutcomes measure: lymph node division, secondaryOutcomes measure: Event-free Survival (EFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Disease-Free Survival(DFS ), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical Ethics Committee of Sun Yat-sen Memorial Hospital, status: RECRUITING, city: Guangzhou, state: Yuexiu, zip: 510120, country: China, contacts name: Song Fan, Doctor, role: CONTACT, phone: 13570536658, phoneExt: +86, email: fansong2@mail.sysu.edu.cn, contacts name: Song Fan, Doctor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06323343, orgStudyIdInfo id: 00040976, briefTitle: Mobile Video Education to Improve Patient Clinician Communication During Prenatal Clinic Visits, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-28, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2025-01-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Medical College of Wisconsin, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test an animated video delivered by text message in patients whose pregnancies are complicated with fetal anomalies. The main question it aims to answer is: Does the video intervention prepare parents to talk to the doctors during prenatal appointments?Participants will be randomized to receive either the video intervention or links to the clinic's webpages. They will complete an enrollment survey before their appointment and a follow up survey after their appointment.The researchers will compare the video and webpage groups to see which group reports engaging in more of the identified best-practices of communication., conditionsModule conditions: Patient Empowerment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: DOUBLE, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 114, type: ESTIMATED, armsInterventionsModule interventions name: Video Intervention, interventions name: Webpage links, outcomesModule primaryOutcomes measure: Parents' communication behaviors measure, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323330, orgStudyIdInfo id: I-1623, briefTitle: Music Therapy for Rehabilitation in Post-stroke Non-fluent Aphasia: the Indian Adaptation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-10-31, completionDateStruct date: 2026-11-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: All India Institute of Medical Sciences, New Delhi, class: OTHER, collaborators name: Institute of Human Behavior and Allied Sciences, collaborators name: Indian Institute of Technology, New Delhi, collaborators name: Vardhman Mahavir Medical College And Safdarjung Hospital, descriptionModule briefSummary: The goal of this Interventional Study is to develop and test the Indian Adaptation of Melodic Intonation Therapy (MIT) for Indian patients in with post-stroke Non-Fluent Aphasia (PSNFA). The main question\[s\] it aims to answer are: • To develop the MIT Indian Adaptation tool and check its feasibility • To compare the MIT with standard speech rehabilitation in patient with PSNFA. Participants will undergo Speech Rehabilitation according to the developed module and the standard treatment will be given in the comparator arm. The speech recovery at 12 weeks will be compared in both treatment arms., conditionsModule conditions: Stroke Rehabilitation, conditions: Aphasia, Broca, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The MIT- Indian Adaptation will be tested and compared with standard speech rehabilitation in post-stroke non-fluent aphasia, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: The outcome assessor will be blinded to the intervention, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Speech rehabilitation, outcomesModule primaryOutcomes measure: Western Aphasia Battery Score, secondaryOutcomes measure: Western Aphasia Battery Score, secondaryOutcomes measure: functional Near Red Spectroscopy measures, secondaryOutcomes measure: modified Rankin Score, secondaryOutcomes measure: Fugl Meyer Assessment Scores, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323291, orgStudyIdInfo id: MCC-23077, briefTitle: Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: H. Lee Moffitt Cancer Center and Research Institute, class: OTHER, collaborators name: Canopy Cancer Collective, descriptionModule briefSummary: This Pilot Study will evaluate a 12-week pilot program that offers digital health coaching for individuals with pancreatic cancer and their caregivers., conditionsModule conditions: Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Coaching Sessions, outcomesModule primaryOutcomes measure: Recruitment Rate, primaryOutcomes measure: Participant Acceptance of the Digital Health Coaching Program, primaryOutcomes measure: Participant Ease of Usability of the Digital Health Coaching Program, primaryOutcomes measure: Feasibility of Utilizing the Digital Health Coaching Program, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Moffitt Cancer Center, status: RECRUITING, city: Tampa, state: Florida, zip: 33612, country: United States, contacts name: Emma Hume, role: CONTACT, phone: 813-745-6426, email: Emma.Hume@moffitt.org, contacts name: Kea Turner, MPH, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Pamela Hodul, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 27.94752, lon: -82.45843, hasResults: False
protocolSection identificationModule nctId: NCT06323265, orgStudyIdInfo id: ARL-SCLC-001, briefTitle: A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Hebei Medical University Fourth Hospital, class: OTHER, descriptionModule briefSummary: The purpose of this study is to assess efficacy and safety of patients who receive Adebrelimab combined with chemotherapy±chest radiotherapy as first-line treatment of extensive stage small cell lung cancer in the real world., conditionsModule conditions: Extensive Stage Small Cell Lung Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Adebrelimab + chemotherapy, interventions name: ±chest radiotherapy, outcomesModule primaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Duration of Overall Response（DoR）, secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jun Wang, status: RECRUITING, city: Shijiazhuang, state: Hebei, country: China, contacts name: Jun Wang, role: CONTACT, phone: 13931182128, email: wangjunzr@163.com, geoPoint lat: 38.04139, lon: 114.47861, hasResults: False